Kennedy Investment Group’s Pfizer PFE Stock Holding History

Kennedy Investment Group’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-6,819	Closed	-$226K	–	126
2023 Q3	$226K	Sell	6,819 -258	-4%	-$9.12K	0.14%	103
2023 Q2	$260K	Buy	7,077 +840	+13%	+$32.7K	0.15%	98
2023 Q1	$254K	Sell	6,237 -1,834	-23%	-$79.2K	0.16%	98
2022 Q4	$414K	Buy	+8,071	New	+$387K	0.26%	85

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Kennedy Investment Group's PFE Position: Q4 2023 in Review

Kennedy Investment Group sold out of Pfizer (PFE) in Q4 2023, closing a stake of 6,819 shares — an estimated $226K sold.

Kennedy Investment Group first reported a position in PFE in Q4 2022 and held it in 4 quarters. The position peaked at $414K in Q4 2022. 2,936 funds tracked by Wall St. Rank hold PFE as of Q4 2023.

Kennedy Investment Group reported no remaining Pfizer position as of Q4 2023 after selling out during the quarter.
Kennedy Investment Group sold 6,819 Pfizer shares in Q4 2023, an estimated $226K.
Kennedy Investment Group first reported a position in Pfizer in Q4 2022 and held it in 4 quarters.
Kennedy Investment Group's Pfizer position peaked at $414K in Q4 2022.
2,936 funds tracked by Wall St. Rank held Pfizer as of Q4 2023.

Based on Kennedy Investment Group's 13F filing for Q4 2023, filed 29 Jan 2024.